Net Cash Provided by (Used in) Investing Activities of RELMADA THERAPEUTICS, INC. from 30 Sep 2013 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Summary
RELMADA THERAPEUTICS, INC. quarterly and annual Net Cash Provided by (Used in) Investing Activities in USD history and change rate from 30 Sep 2013 to 31 Mar 2025.
  • RELMADA THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities for the quarter ending 31 Mar 2025 was $15,359,713, a 53% increase year-over-year.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Investing Activities for 2024 was $51,561,597, a 2.2% increase from 2023.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Investing Activities for 2023 was $50,453,332, a 156% increase from 2022.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Investing Activities for 2022 was $19,733,609.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Investing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Investing Activities, Annual (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Annual Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Net Cash Provided by (Used in) Investing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $15,359,713 +$5,301,262 +53% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $10,058,451 -$29,945,098 -75% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q1 2023 $40,003,549 +$50,031,217 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q1 2022 $10,027,668 -$25,493,509 -165% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $15,465,841 +$39,098,056 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q1 2020 $23,632,215 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q3 2017 $2,591* +$22,236 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2019 Q1
Q3 2016 $24,827 -$23,517 01 Jul 2016 30 Sep 2016 10-Q 10 Nov 2016 2017 Q1
Q3 2015 $1,310* +$10,668,690 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2017 Q1
Q3 2014 $10,670,000 -$10,669,238 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2016 Q1
Q1 2014 $649* 01 Jan 2014 31 Mar 2014 8-K 27 May 2014 2014 Q3
Q3 2013 $762* 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2015 Q1

RELMADA THERAPEUTICS, INC. Annual Net Cash Provided by (Used in) Investing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $51,561,597 +$1,108,265 +2.2% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $50,453,332 +$30,719,723 +156% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $19,733,609 +$73,851,645 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $54,118,036 -$19,670,388 -57% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $34,447,648 +$45,717,175 +57% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022 2021 FY
2019 $80,164,823 -$80,152,432 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021 2020 FY
2018 $12,391* +$37,299 01 Jul 2017 30 Jun 2018 10-KT 26 Mar 2020 2019 FY
2017 $49,690 +$512,566 +91% 01 Jul 2016 30 Jun 2017 10-K 28 Sep 2018 2018 FY
2016 $562,256 -$538,930 -2310% 01 Jul 2015 30 Jun 2016 10-K 09 Sep 2016 2016 FY
2015 $23,326 01 Jul 2014 30 Jun 2015 10-K 09 Sep 2016 2016 FY
2013 $8,871,000 01 Jan 2013 31 Dec 2013 10-K 11 Sep 2015 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.